Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
Significant Improvement in Progression Free Survival Seen in Relapsed or Refractory Patients
Genzyme Corporation announced that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients met its primary endpoint by demonstrating a significant improvement in progression free survival (PFS).
The trial’s independent data safety monitoring board, in a pre-planned interim analysis, determined that the study achieved its primary endpoint (p<0.0173) and recommended early closure of the trial. Patients in the international, multi-center study treated with Campath in combination with Fludara (FluCAM) experienced a significant increase in the amount of time they lived without the disease progressing compared to patients treated with Fludara alone. The trial was designed to detect at least a 50 percent overall improvement in progression free survival in the FluCAM arm in comparison to the Fludara arm.
Study results from this interim analysis are expected to be submitted to the American Society of Hematology meeting held in December.
“The standard of care for patients with chronic lymphocytic leukemia is evolving, as active single agents are studied in combination,” said Cyndi Sirard, MD, Medical Director, Genzyme Transplant and Oncology. “Campath has proven to be a highly active single agent therapy across the spectrum of this disease, and Fludara is considered a backbone of CLL therapy. These trial results are anticipated to provide clinically meaningful data supporting Campath use in combination with Fludara in patients with relapsed or refractory CLL.”
Based on the study’s positive findings, Genzyme intends to seek regulatory approval in the United States, European Union, and other countries to further broaden the Campath label to include the use of this combination regimen. If the expanded label is granted, Campath, marketed as MabCampath® in Europe, would be the first humanized monoclonal antibody approved as both a single agent and in combination therapy for the treatment of CLL.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Devgen and Sang Hyang Seri announce hybrid rice production cooperation in Indonesia
Could viruses be used to treat acne?
Caffeine appears to be beneficial in males - but not females - with Lou Gehrig's disease
Researchers study the human factor in spread of pandemic illness

How CRISPR can help fight against neurodegenerative diseases - Scientists listed ways of applying genetic engineering to treat Parkinson's disease

Stem Cells May Speed Up Screening of Drugs for Rare Cancers

AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus
Removab Approval: Proof-of-Concept for Technology Transfer in Germany

Decoding Blood Platelet Production: The Intricate Role of Lipids - Disruptions in lipid metabolism might affect platelet production

Excessive fluid consumption: habit or hormonal disorder? - Which test provides a reliable diagnosis?
